Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib and Nivolumab in Oral Cavity Cancer (SNOW)
NCT03575598Phase 1Completed
- Sponsor
- University Health Network
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitravatinib in squamous cell carcinoma of the oral cavity (OSCC), sponsored by University Health Network. Primary endpoint: Pharmacodynamic and immune effects of pre-operative therapy at 2 years. Started Aug 2018; status: completed.
02
Drugs
sitravatinib
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT03575598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575598.